Does Lupus Cause Low White Blood Cells?

Lupus frequently causes low white blood cell counts, a finding so characteristic that it is built into the classification criteria doctors use to diagnose the disease. Depending on the study, somewhere between a fifth and half of people with systemic lupus erythematosus (SLE) will have a low total white blood cell count at some point, and the proportion climbs higher when researchers look specifically at lymphocytes. The reasons are not simple, though, because the immune system in lupus attacks itself at multiple levels, from the bloodstream to the bone marrow.

How Common Are Low White Blood Cells in Lupus

The term doctors use is leukopenia, meaning a total white blood cell count below the normal range. A systematic literature review covering multiple international cohorts placed the prevalence of leukopenia in lupus patients at roughly 22 to 42 percent.¹ A large cross-sectional study of Han Chinese lupus patients found a leukopenia prevalence of 40 percent, with the median white blood cell count in affected patients sitting at less than half the level seen in healthy controls.² These are not rare lab curiosities. For many people with lupus, low white blood cells are part of the fabric of the disease from the time they are diagnosed.

One reason the reported ranges are so wide is that different studies use different thresholds for “low,” different populations have different baseline counts, and some studies look at a single snapshot while others track patients over years. In one long-term cohort, the cumulative prevalence of leukopenia climbed to about 57 percent when researchers counted every patient who experienced it at least once during follow-up, rather than just at diagnosis.

Which White Blood Cells Drop, and Why It Matters

White blood cells are not a single cell type. A complete blood count breaks them into several subtypes, and lupus does not hit them all equally. The two most clinically relevant drops are in lymphocytes and neutrophils.

Lymphocytes are the cells that coordinate immune responses and remember past infections. Low lymphocyte counts, called lymphopenia, are the most frequent blood abnormality in lupus. The same systematic review found lymphopenia prevalence ranging from 15 to 82 percent across published cohorts, a strikingly wide spread that reflects differences in how studies defined it.¹ In the Chinese cohort, over 55 percent of patients had low lymphocyte counts, and those patients’ median lymphocyte levels were only about 30 percent of normal.²

Neutrophils, the first responders that rush to fight bacterial infections, also drop in about 20 to 40 percent of lupus patients.¹ Neutropenia matters because it is a more immediate risk factor for serious bacterial infections than lymphopenia is. A person whose lymphocyte count is moderately low can usually fight off everyday germs reasonably well, but a person whose neutrophil count falls sharply may not mount an effective early defense against bacteria.

The distinction between lymphopenia and neutropenia is not just academic. They tend to arise through different mechanisms, respond to different treatments, and carry different implications for day-to-day infection risk.

How Lupus Attacks Its Own White Blood Cells

In lupus the immune system produces antibodies against the body’s own tissues, and white blood cells are a common target. Several overlapping mechanisms drive the counts down.

The most direct route involves antilymphocyte antibodies. These are autoantibodies that bind to the surface of lymphocytes and mark them for destruction. Cold-reactive lymphocytotoxic antibodies are found in the blood of most people with active lupus.³ Once bound, these antibodies can trigger several outcomes: the complement system may punch holes in the cell membrane, other immune cells may destroy the tagged lymphocyte, or the antibody may alter the surface proteins on the cell so that it stops functioning properly.⁴

Neutropenia in lupus often involves a different autoantibody. Patients with chronic low neutrophil counts show a strong association with anti-Ro (also called anti-SSA) antibodies.⁵ Research has shown that anti-Ro antibodies can cross-react with a protein on the neutrophil surface, binding to it and activating the complement cascade, which destroys the cell.⁶ This is a distinct mechanism from the antilymphocyte antibodies and helps explain why some lupus patients have low lymphocytes, some have low neutrophils, and some have both.

When the Bone Marrow Itself Is Affected

The bloodstream is not the only battlefield. Lupus can also suppress white blood cell production at the source. The bone marrow is where all blood cells are made, and in lupus the marrow environment can be disrupted in several ways.

Circulating immune complexes and autoantibodies can act on cells within the marrow, potentially triggering a fibrotic response where normal marrow tissue is gradually replaced by scar-like fibrous tissue.⁷ When this happens, the marrow simply cannot produce enough blood cells, and the result is low counts across multiple cell lines, not just white blood cells but sometimes also red blood cells and platelets.

Inflammatory signals in the marrow can also skew production in unhelpful ways. Research suggests that certain cytokines in the lupus bone marrow microenvironment push stem cell development away from lymphocyte production and toward the creation of a specific, problematic neutrophil subtype called low-density granulocytes. These cells are implicated in tissue damage rather than infection defense, so the net effect is fewer functional lymphocytes and more pro-inflammatory neutrophils that make the disease worse.⁸

Bone marrow involvement is less common than peripheral blood destruction, but when it happens it tends to be harder to treat and may explain why some patients have persistently low counts that do not bounce back during disease remission.

Do Low Counts Track with Disease Flares

For many lupus patients, white blood cell counts function as a rough barometer of disease activity. A dropping count can be one of the early signals that the disease is becoming more active, sometimes before other symptoms catch up.

A prospective study found that the neutrophil-to-lymphocyte ratio was positively associated with both disease activity scores and severe disease flares in lupus patients.⁹ In patients with high disease activity scores, leukopenia and low platelet counts frequently appeared together.¹⁰ A Japanese study similarly found that patients who experienced lupus flares had significantly lower white blood cell counts than those who remained stable.¹¹

That said, the relationship is not perfectly linear. Some patients have persistently low counts even during relatively quiet periods, while others maintain normal counts during mild or moderate flares. Doctors treat declining counts as one piece of the puzzle alongside complement levels, anti-DNA antibody titers, and clinical symptoms. A falling white blood cell count alone is not enough to call a flare, but if it is dropping alongside other markers, it adds confidence to the picture.

Infection Risk and the Leukopenia Paradox

If your immune cells are low, you would expect a straightforward increase in infections. The reality is more nuanced than that, and the evidence has surprised researchers.

One long-term evaluation found that the rate of serious infections in lupus patients was about 12 per 100 patient-years, which is substantially higher than the general population. But the survival rate free of serious infection was no different between patients who had experienced leukopenia and those who had not. Persistent lymphopenia (continuously low lymphocytes for at least three-quarters of the observation period) was present in about 42 percent of patients, yet persistent neutropenia was essentially absent, suggesting that lymphocyte counts tend to stay low while neutrophil counts fluctuate more over time.

This finding does not mean that low white blood cells are harmless. Rather, it reflects the messy reality that lupus patients face infection risk from many directions simultaneously: immunosuppressive medications, steroid use, kidney involvement, and the disease’s general toll on the immune system. When every patient already has multiple risk factors, the independent contribution of leukopenia alone can be hard to measure. The practical takeaway is that lupus patients should be vigilant about signs of infection regardless of whether their white blood cell count is normal at any given moment. Fever, chills, and unusual fatigue deserve prompt medical attention.

Why Treatment Gets Complicated

Managing low white blood cells in lupus creates a genuine clinical tension. Many of the drugs used to control lupus, including cyclophosphamide, azathioprine, mycophenolate, and methotrexate, can themselves lower white blood cell counts as a side effect. So when a lupus patient shows up with a low count, the doctor faces a question: is this the disease or the medication?

If the count drop is driven by disease activity, the answer is often to increase immunosuppression. If the drop is a drug side effect, the answer is the opposite. Getting this wrong in either direction is bad: undertreating disease activity leads to organ damage, while overimmunosuppressing a patient with drug-induced leukopenia pushes them further into dangerous territory.

There is also an important caution about a treatment that works well in other contexts. Granulocyte colony-stimulating factor (G-CSF) is widely used for febrile neutropenia in patients with cancer. It stimulates the bone marrow to produce more neutrophils. But in lupus, G-CSF has been linked to disease flares, including cases of severe kidney damage. Reports describe patients with SLE who developed irreversible loss of renal function after G-CSF therapy, and reviews of published cases have found that a meaningful fraction of lupus patients treated with G-CSF experienced flares or cutaneous vasculitis.¹² Case reports have reinforced the pattern, with patients developing worsening skin symptoms after receiving the drug.¹³ The reason likely relates to G-CSF’s ability to stimulate the very immune pathways that drive lupus inflammation. Rheumatologists now generally approach G-CSF in lupus patients with considerable caution, reserving it for situations where severe neutropenia poses an immediate life-threatening infection risk.

Hydroxychloroquine (Plaquenil), on the other hand, appears to work in the right direction. The same Japanese study found that patients using hydroxychloroquine had a lower rate of disease flares, and the drug permitted reduction in corticosteroid doses.¹¹ Because hydroxychloroquine calms the overactive immune response without broadly suppressing blood cell production, it is one of the safer baseline therapies for keeping counts stable.

When Counts Crash Suddenly

Most lupus-related leukopenia is chronic and mild to moderate. Counts sit below normal but not at life-threatening levels. Occasionally, though, white blood cells plummet as part of a more dangerous complication called macrophage activation syndrome (MAS).

MAS is a hyperinflammatory state where macrophages, a type of immune cell, become overactivated and begin destroying blood cells in the marrow and bloodstream. In lupus patients, MAS tends to present with unexplained high fever, dropping counts across all blood cell lines, liver dysfunction, and extremely elevated ferritin levels. A multicenter study found that patients at the onset of MAS had significantly higher rates of severe drops in blood counts compared to their pre-MAS baseline.¹⁴ MAS is a medical emergency. It is rare, but it is the scenario where low white blood cells in lupus become acutely dangerous rather than chronically inconvenient.

The challenge with MAS is that its early symptoms overlap with a lupus flare and also with severe infection. All three can cause fever, falling blood counts, and organ stress. Distinguishing between them matters because they require very different treatments. Ferritin levels offer one clue: in MAS they tend to skyrocket to levels far above what a typical flare or infection would produce. But the overlap is messy enough that it often requires a coordinated workup including blood cultures, additional labs, and sometimes a bone marrow biopsy.

Lupus in Children and Low Blood Counts

Lupus that begins in childhood tends to be more aggressive than adult-onset disease across many organ systems, and blood abnormalities are no exception. Interestingly, the pattern of low counts varies by age within pediatric lupus itself. A study comparing three age groups of pediatric lupus patients found that leukopenia was more frequent in the postpubertal group than in younger children.¹⁵

For parents of children with lupus, this has practical implications. Blood count monitoring in pediatric lupus needs to be frequent, and the thresholds for concern are adjusted for age because children’s normal ranges differ from adults’. A count that would be mildly low in an adult might be more concerning in a younger child, and the medications used in pediatric lupus require more careful dose adjustments because children’s bone marrow can be more sensitive to immunosuppressive drugs.

Bone Marrow Biopsies and What They Reveal

Most lupus patients with low white blood cells will never need a bone marrow biopsy. The diagnosis of lupus-related leukopenia is usually made with straightforward blood tests, disease activity assessments, and a careful medication review. But when counts are persistently and severely low, when multiple blood cell lines are affected, or when the clinical picture does not fit neatly with lupus alone, a marrow biopsy can provide useful information.

One study examining bone marrow biopsies in lupus patients with blood abnormalities found that the histological features were strikingly similar to those seen in rheumatoid arthritis, another autoimmune disease.¹⁶ This is a reminder that the bone marrow changes in lupus are not unique signatures. A biopsy helps rule out other causes of low counts, such as a primary blood cancer, drug toxicity, or an unrelated marrow disorder, more than it confirms lupus as the specific culprit.

The biopsy can also reveal the degree of fibrosis in the marrow. As noted earlier, immune complexes in lupus can trigger fibrous tissue replacement. When marrow fibrosis is present, the prognosis for count recovery is generally worse, because the physical architecture of the marrow has been altered. This information can help guide how aggressively doctors pursue treatment and whether they need to consider therapies beyond standard lupus management.